---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054513"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:35:33.424824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M

## Summary
- Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).
- clonoSEQ test volume rose 41% to 17,040; net loss improved to $47.5M from $57.7M.
- Cash $308.9M; FY2024 MRD revenue guidance raised to $135-140M, opex lowered to $350-360M.
- FDA ODAC unanimously supported MRD as primary endpoint for accelerated approval in multiple myeloma.
- Strategic move: MRD and Immune Medicine to report separately; antibody discovery launched for MS and type 1 diabetes.

## SEC filing metadata
- accession: 0000950170-24-054513
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/adpt-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054513
- JSON: https://secwatch.observer/filing/0000950170-24-054513.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054513.txt

## Key facts
- Earnings Releases
  Adaptive Biotechnologies Corp reported quarter ended March 31, 2024 results: revenue $41.9 million, net income $47.5 million loss.
  - Period: quarter ended March 31, 2024
  - Revenue: $41.9 million
  - Net income: $47.5 million loss
  - Result: reported results
  source text: First Quarter 2024 Financial Results Revenue was $41.9 million for the quarter ended March 31, 2024, representing an 11% increase from the first quarter in the prior year. MRD revenue was $32.6 million for the quarter, representing a 52% increase from the first quarter in the prior year. Immune Medicine revenue was $9.2 million for the quarter, representing a 43% decrease from the first quarter in the prior year. Operating expenses were $90.6 million for the first quarter of 2024, compared to $94.8 million in the first quarter of the prior year, representing a decrease of 4%. MRD operating expenses were $59.9 million for the quarter, representing a 7% increase from the first quarter in the prior year. Immune Medicine operating expenses were $23.8 million for the quarter, representing a 25% decrease from the first quarter in the prior year. Interest and other income, net was $4.2 million for the first quarter of 2024, compared to $3.0 million in the first quarter of the prior year. Inte
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm
- Earnings Releases
  Adaptive Biotechnologies Corp updated its full year 2024 guidance (lowered).
  - Period: full year 2024
  - Guidance: lowered
  - Result: guidance update
  source text: Adaptive Biotechnologies expects full year revenue for the MRD business to be between $135 million and $140 million, updated from the previous range between $130 million and $140 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm
- Earnings Releases
  Adaptive Biotechnologies Corp updated its full year 2024 guidance (lowered).
  - Period: full year 2024
  - Guidance: lowered
  - Result: guidance update
  source text: We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $360 million, updated from the previous range between $360 million and $370 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.